Osteoarthritis Treatment Market

Executive Summary

Osteoarthritis Treatment Market was valued at US $7.29 billion in 2021 and is projected to grow at 8.85% CAGR over the forecast period to reach US $12.13 billion by 2027. Osteoarthritis Treatment Market represented US $1.14 billion opportunity over 2019-2021 and estimated to create US $4.83 billion opportunity in 2027 over 2021.

Osteoarthritis Treatment from Consainsights analyses the Osteoarthritis Treatment Market in the Life Sciences industry over the forecast period to 2027.

Osteoarthritis Treatment research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Osteoarthritis Treatment segmentation includes Drugs, Anatomy and Geography.

Based on the Drugs, the Osteoarthritis Treatment analysis covers Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Hyaluronic Acid Injection, Other Drugs.

In Drugs segment, Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment has highest cagr growth of 7.83%.

Based on the Anatomy, the Osteoarthritis Treatment analysis covers Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, Other Anatomies.

In Anatomy segment, Ankle Osteoarthritis segment has highest cagr growth of 7.83%.

Based on the region, the Osteoarthritis Treatment analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Bayer AG, OrthogenRx, Abbott Laboratories, Glaxosmithkline plc, Sanofi SA, Pfizer Inc., Zimmer Biomet, Anika Therapeutics Inc., Mylan (Viatris), Novartis AG, Assertio Holdings Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Drugs

Introduction

In 2021, Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment has the highest revenue of US $2.73 billion and is expected to grow at CAGR of 7.83% by 2027 Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment has highest cagr growth of 7.83%.

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment was valued at US $2.31 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $4.55 billion by 2027. Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment represented US $0.43 billion opportunity over 2019-2021 and estimated to create US $1.81 billion opportunity in 2027 over 2021.

Corticosteroids

Corticosteroids segment was valued at US $1.76 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $3.47 billion by 2027. Corticosteroids segment represented US $0.33 billion opportunity over 2019-2021 and estimated to create US $1.38 billion opportunity in 2027 over 2021.

Hyaluronic Acid Injection

Hyaluronic Acid Injection segment was valued at US $1.39 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $2.74 billion by 2027. Hyaluronic Acid Injection segment represented US $0.26 billion opportunity over 2019-2021 and estimated to create US $1.09 billion opportunity in 2027 over 2021.

Other Drugs

Other Drugs segment was valued at US $0.69 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $1.37 billion by 2027. Other Drugs segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.54 billion opportunity in 2027 over 2021.

Anatomy

Introduction

In 2021, Ankle Osteoarthritis segment has the highest revenue of US $3.26 billion and is expected to grow at CAGR of 7.83% by 2027 Ankle Osteoarthritis segment has highest cagr growth of 7.83%.

Ankle Osteoarthritis

Ankle Osteoarthritis segment was valued at US $2.75 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $5.42 billion by 2027. Ankle Osteoarthritis segment represented US $0.51 billion opportunity over 2019-2021 and estimated to create US $2.16 billion opportunity in 2027 over 2021.

Hip Osteoarthritis

Hip Osteoarthritis segment was valued at US $1.68 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $3.30 billion by 2027. Hip Osteoarthritis segment represented US $0.31 billion opportunity over 2019-2021 and estimated to create US $1.32 billion opportunity in 2027 over 2021.

Knee Osteoarthritis

Knee Osteoarthritis segment was valued at US $0.71 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $1.40 billion by 2027. Knee Osteoarthritis segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.56 billion opportunity in 2027 over 2021.

Shoulder Osteoarthritis

Shoulder Osteoarthritis segment was valued at US $0.81 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $1.60 billion by 2027. Shoulder Osteoarthritis segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.64 billion opportunity in 2027 over 2021.

Other Anatomies

Other Anatomies segment was valued at US $0.20 billion in 2019 and is projected to grow at 7.83% CAGR over the forecast period to reach US $0.40 billion by 2027. Other Anatomies segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.16 billion opportunity in 2027 over 2021.